Pieris inks respiratory partnership with Genentech, adding another to slate of milestone-heavy deals

Four years after striking an up to $2 billion respiratory partnership with AstraZeneca, Pieris Pharmaceuticals has added another deal with a marquee pharma partner: Genentech.

Genentech agreed to pay $20 million upfront in milestones to access Pieris’ protein technology for respiratory diseases, where the small biotech already has multiple...

Click to view original post